AU5611398A - Method of treating or inhibiting neutropenia - Google Patents

Method of treating or inhibiting neutropenia

Info

Publication number
AU5611398A
AU5611398A AU56113/98A AU5611398A AU5611398A AU 5611398 A AU5611398 A AU 5611398A AU 56113/98 A AU56113/98 A AU 56113/98A AU 5611398 A AU5611398 A AU 5611398A AU 5611398 A AU5611398 A AU 5611398A
Authority
AU
Australia
Prior art keywords
treating
neutropenia
inhibiting
inhibiting neutropenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56113/98A
Inventor
Joseph William Epstein
James Joseph Gibbons
Jeremy Ian Levin
Judy Lucas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of AU5611398A publication Critical patent/AU5611398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU56113/98A 1996-12-19 1997-12-17 Method of treating or inhibiting neutropenia Abandoned AU5611398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77074396A 1996-12-19 1996-12-19
US08770743 1996-12-19
PCT/US1997/023419 WO1998026781A1 (en) 1996-12-19 1997-12-17 Method of treating or inhibiting neutropenia

Publications (1)

Publication Number Publication Date
AU5611398A true AU5611398A (en) 1998-07-15

Family

ID=25089545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56113/98A Abandoned AU5611398A (en) 1996-12-19 1997-12-17 Method of treating or inhibiting neutropenia

Country Status (7)

Country Link
EP (1) EP0957918A1 (en)
JP (1) JP2001506998A (en)
AR (1) AR010808A1 (en)
AU (1) AU5611398A (en)
CA (1) CA2273288A1 (en)
WO (1) WO1998026781A1 (en)
ZA (1) ZA9711342B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2650962C2 (en) * 2012-06-07 2018-04-18 Чилдрен'З Хоспитал Лос Анджелес Methods for treating neutropenia using retinoid agonists
EP3107533A4 (en) 2014-02-18 2017-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2615291B1 (en) * 1987-05-15 1989-07-13 Thomson Csf METHOD FOR TESTING OPERATION OF A RADAR INFORMATION DISPLAY DEVICE AND IMPLEMENTATION OF THIS METHOD
EP0329940B1 (en) * 1988-02-22 1994-01-05 American Cyanamid Company 5-(substituted)amino)-8- (phenyl or substituted phenyl)-3H,6H-1,2,5,a,8 a-tetraazaacenaphthylen-3-ones
US4916137A (en) * 1988-02-22 1990-04-10 American Cyanamid Company 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders

Also Published As

Publication number Publication date
CA2273288A1 (en) 1998-06-25
WO1998026781A1 (en) 1998-06-25
ZA9711342B (en) 1999-06-17
AR010808A1 (en) 2000-07-12
JP2001506998A (en) 2001-05-29
EP0957918A1 (en) 1999-11-24

Similar Documents

Publication Publication Date Title
ZA965088B (en) Methods of preventing or treating allergles
AU5439996A (en) Compositions and methods for treating pain
AU9214398A (en) Compositions and methods for treating water
GB9617780D0 (en) Method of treatment
AU4340897A (en) Method and composition for inhibiting decomposition of aspartame
AUPN271295A0 (en) Method of treatment
AU4518897A (en) Method of treating atherosclerosis
AU2807297A (en) Methods of treating wastewater
AU1714697A (en) Method and composition for the treatment of osteoarthritis
AU4636199A (en) Method of reducing or preventing malodour
AU5594398A (en) Methods and compositions for preventing and treating bone loss
AU5528996A (en) Methods of treating or preventing pain or nociception
AU2051397A (en) Method of treating alopecia
AU4027097A (en) Method of treatment
AU4525299A (en) Method of reducing or preventing malodour
AU5791698A (en) Methods and compositions for preventing and treating bone loss
AU2243897A (en) Methods of treating or preventing pain or nociception
ZA973988B (en) Method of treatment
AU2750297A (en) Methods for prevention and/or treatment of neutropenia
AU5611398A (en) Method of treating or inhibiting neutropenia
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
EP0974364A4 (en) Method of inhibiting drug precipitation
AUPO124196A0 (en) Method of ground treatment
AU3779595A (en) Method of treating turf
AU5369198A (en) Methods and compositions for preventing and treating bone loss